Evaluation of subclinical cardiovascular disease by carotid intima media thickness, epicardial adipose tissue thickness, serum endocan, and nesfatin-1 levels in patients with primary hyperparathyroidism

Basit Öğe Kaydı
dc.contributor.authorKocabas, Muhammet
dc.contributor.authorAlsancak, Yakup
dc.contributor.authorCan, Mustafa
dc.contributor.authorCordan, Ilker
dc.contributor.authorBurgucu, Hatice Caliskan
dc.contributor.authorKarakose, Melia
dc.contributor.authorYerlikaya, Fatma Humeyra
dc.date.accessioned2024-02-23T14:41:44Z
dc.date.available2024-02-23T14:41:44Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractBackground/aim: Data on the presence and extent of cardiovascular disease (CVD) risk in primary hyperparathyroidism (PHPT) are conflicting. In our study, we aimed to investigate the increased CVD risk in patients with PHPT by carotid intima-media thickness (CIMT), epicardial adipose tissue (EAT) thickness, and serum levels of endocan and nesfatin-1. Materials and methods: Patients with PHPT (n = 44) and age- and sex-matched healthy control subjects (n = 40) were enrolled in this study. Demographic data of the participants were questioned. Serum endocan and nesfatin-1 concentrations were assessed using commercially available ELISA kits. Noninvasive measurements of CIMT and EAT thickness were made with high-resolution ultrasonography and B-mode echocardiography. Results: There was no statistically significant difference in serum endocan and nesfatin-1 levels and EAT thickness in the PHPT group compared to controls. CIMT was statistically significantly higher in the PHPT group compared to controls (p = 0.001). A negative correlation was found between PTH and low-density lipoprotein cholesterol level (p = 0.001) but no significant relationship was found between other parameters. Conclusion: We found that CIMT is increased in patients with PHPT and consequently, CVD risk is high in these patients. More comprehensive studies are needed to identify other markers that predict increased CVD risk in patients with PHPT.en_US
dc.identifier.doi10.55730/1300-0144.5405
dc.identifier.endpage1040en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.pmid36326370en_US
dc.identifier.scopus2-s2.0-85136801885en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1033en_US
dc.identifier.urihttps://doi.org/10.55730/1300-0144.5405
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16975
dc.identifier.volume52en_US
dc.identifier.wosWOS:000881194200020en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPrimary Hyperparathyroidismen_US
dc.subjectCarotid Intima Media Thicknessen_US
dc.subjectEpicardial Adipose Tissue Thicknessen_US
dc.subjectEndocanen_US
dc.subjectNesfatin-1en_US
dc.subjectCardiovascular Disease Risken_US
dc.titleEvaluation of subclinical cardiovascular disease by carotid intima media thickness, epicardial adipose tissue thickness, serum endocan, and nesfatin-1 levels in patients with primary hyperparathyroidismen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu